Arriving in the landscape of obesity management, retatrutide is a different method. Unlike many available medications, retatrutide operates as a twin agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) sensors. This dual engagement encourages multiple beneficial effects, such